EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors

Published:2018-07-15 Issue:3 Volume:50 Page:908-916
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Yang Jiyoul,Lee Ok-Jun,Son Seung-Myoung,Woo Chang Gok,Jeong Yusook,Yang Yaewon,Kwon Jihyun,Lee Ki Hyeong,Han Hye Sook

Funder

Chungbuk National University

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://e-crt.org/upload/pdf/crt-2017-378.pdf

Reference29 articles.

1. Cancer statistics, 2017

2. One Hundred Years of Lung Cancer

3. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

4. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

5. Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis;MedComm;2024-07-20

2. Identification of Potential Biomarkers of EGFR Mutation in Pleural Effusion of Non-Small Cell Lung Cancer Patients Based on Metabolomics;Clinical Laboratory;2024

3. Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion;Scientific Reports;2023-07-26

4. EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery;Annals of Surgical Oncology;2023-06-25

5. Best practices in epidermal growth factor receptor T790M testing for advanced non–small-cell lung cancer in Hong Kong;Hong Kong Medical Journal;2023-06-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3